These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28629333)

  • 21. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial.
    Kwak N; Jeon D; Park Y; Kang YA; Kim KJ; Kim YR; Kwon BS; Kwon YS; Kim HJ; Lee JH; Lee JY; Lee JK; Mok J; Cheon M; Park J; Hahn S; Yim JJ
    Trials; 2022 Aug; 23(1):666. PubMed ID: 35978342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Results of a therapeutic trial comparing a 6-month regimen to a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Final report: results 3 years after the onset of treatment].
    Berkani M; Chaulet P; Darbyshire JH; Nunn A; Fox W
    Rev Mal Respir; 1986; 3(2):73-85. PubMed ID: 3726263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A controlled clinical trial of long course chemotherapy regimens containing rifabutin in the treatment of multi-drug resistant pulmonary tuberculosis].
    Zhu LZ; Fu Y; Chu NH; Ye ZZ; Xiao HP; Wang W; Yuan SL; Zhang X; Luo YA; Ma LP
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Aug; 29(8):520-3. PubMed ID: 17074263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Algerian working group/British Medical Research Council cooperative study.
    Am Rev Respir Dis; 1984 Jun; 129(6):921-8. PubMed ID: 6375490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis.
    Gao J; Ma Y; Du J; Zhu G; Tan S; Fu Y; Ma L; Zhang L; Liu F; Hu D; Zhang Y; Li X; Li L; Li Q
    BMC Pulm Med; 2016 Feb; 16():26. PubMed ID: 26846562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary Tuberculosis.
    Olliaro PL; Merle C; Mthiyane T; Bah B; Kassa F; Amukoye E; N Diaye A; Perronne C; Lienhardt C; McIlleron H; Fielding K
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-course Regimen for Subsequent Treatment of Pulmonary Tuberculosis: A Prospective, Randomized, Controlled Multicenter Clinical Trial in China.
    Yan L; Kan X; Zhu L; Xu K; Yin J; Jie L; Li Y; Yue J; Cui W; Du J; Wang L; Tan S; Jiang X; Zeng Z; Xu S; Wang L; Chen Y; He W; Gao X; Bai D; Zhao C; Yan X; Zhu Y; Fan Y; Xie L; Deng A; Zhang Q; Xiao H
    Clin Ther; 2018 Mar; 40(3):440-449. PubMed ID: 29519716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.
    Jindani A; Nunn AJ; Enarson DA
    Lancet; 2004 Oct 2-8; 364(9441):1244-51. PubMed ID: 15464185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement cues of lesion absorption using the adjuvant therapy of traditional Chinese medicine Qinbudan tablet for retreatment pulmonary tuberculosis with standard anti-tuberculosis regimen.
    Zhang SY; Fu JY; Guo XY; Wu DZ; Zhang T; Li C; Qiu L; Shao CR; Xiao HP; Chu NH; Deng QY; Zhang X; Yan XF; Wang ZL; Zhang ZJ; Jiang X; Zheng YJ; Zheng PY; Zhang HY; Lu ZH
    Infect Dis Poverty; 2020 May; 9(1):50. PubMed ID: 32381098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society.
    Br J Dis Chest; 1984 Oct; 78(4):330-6. PubMed ID: 6386028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of levofloxacin versus rifampicin in tuberculous meningitis: an open-label randomized controlled trial.
    Kalita J; Misra UK; Prasad S; Bhoi SK
    J Antimicrob Chemother; 2014 Aug; 69(8):2246-51. PubMed ID: 24752957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance.
    Stagg HR; Bothamley GH; Davidson JA; Kunst H; Lalor MK; Lipman MC; Loutet MG; Lozewicz S; Mohiyuddin T; Abbara A; Alexander E; Booth H; Creer DD; Harris RJ; Kon OM; Loebinger MR; McHugh TD; Milburn HJ; Palchaudhuri P; Phillips PPJ; Schmok E; Taylor L; Abubakar I;
    Eur Respir J; 2019 Oct; 54(4):. PubMed ID: 31371444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The effectiveness of pyrazinamide-containing six-month short course chemotherapy].
    Wada M
    Kekkaku; 2000 Nov; 75(11):665-73. PubMed ID: 11140090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis.
    Thai PVK; Ha DTM; Hanh NT; Day J; Dunstan S; Nhu NTQ; Kiet VS; Lan NH; Dung NH; Lan NTN; Thuong NT; Lan NN; Liễu PTT; Hồng NT; Điệp ĐC; Thanh NTK; Hội NV; Nghĩa NV; Đại TN; Minh HQ; Thơm NV; Farrar J; Caws M
    BMC Infect Dis; 2018 Mar; 18(1):112. PubMed ID: 29510687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment.
    Zierski M; Bek E; Long MW; Snider DE
    Am Rev Respir Dis; 1980 Dec; 122(6):879-89. PubMed ID: 7006476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultrashort-course chemotherapy for culture-negative pulmonary tuberculosis--a qualified success.
    Cowie RL; Langton ME; Escreet BC
    S Afr Med J; 1985 Dec; 68(12):879-80. PubMed ID: 4071345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar.
    Al-Shaer MH; Mansour H; Elewa H; Salameh P; Iqbal F
    BMC Infect Dis; 2017 Feb; 17(1):118. PubMed ID: 28152986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association.
    Lancet; 1976 Nov; 2(7995):1102-4. PubMed ID: 62946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.